1.14
+4.59%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Stereotaxis
From its filings with the US Securities and Exchange Commission
Stereotaxis is based in St.louis, Missouri and is incorporated in Delaware. Its shares trade on NYSE under the ticker STXS. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 31 December 2025, it reported revenue of $32.4m and a net loss of $21.6m. At that date it held total assets of $52.3m and shareholders' equity of $13.5m. By business, Disposables Service and Accessories [Member] brought in 68.4% of revenue, followed by Systems [Member] at 31.6%.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 12 Aug 2004
- Employees
- 131
- Website
- stereotaxis.com ↗
- Head office
- 710 N TUCKER BLVD, ST.LOUIS, MO, 63101
- Incorporated in
- DE
- Classification
- Electromedical & Electrotherapeutic Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. David FischelChairman of the Board, Chief Executive Officer, since 2016$62,195
- Ms. Kimberly PeeryChief Financial Officer$340,165
- Mr. David BenferLead Independent Director$200,000
- Dr. Nathan FischelDirector$200,000
- Mr. Nachum ShamirDirector$90,761
- Dr. Myriam CuretIndependent Director$200,000
- Mr. Ross LevinIndependent Director$200,000
- Dr. Arun MenawatIndependent Director$200,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 58
- Social
- 53
- Governance
- 46
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Stereotaxis Inc is a leading medical technology company specializing in robotic navigation systems.
- The company's products offer precise and accurate control during minimally invasive procedures, reducing the risk of complications.
- Stereotaxis' technology also allows for improved visualization, enabling physicians to perform complex procedures with greater efficiency.
Weaknesses
- Stereotaxis' robotic systems require significant investment, making them expensive for smaller healthcare facilities.
- Adoption of the technology may be limited in regions with limited healthcare budgets or outdated infrastructure.
- The company heavily relies on research and development, which can result in delays in product launches.
Opportunities
- The demand for minimally invasive procedures is growing, creating opportunities for Stereotaxis to expand its market share.
- Emerging markets, such as Asia and Latin America, present untapped potential for the adoption of robotic navigation systems in healthcare.
- Collaboration with other medical device companies can potentially enhance Stereotaxis' product offerings and increase its competitive advantage.
Threats
- Competition from other medical device manufacturers offering similar technologies poses a threat to Stereotaxis' market position.
- Changes in healthcare regulations and reimbursement policies can impact the adoption and affordability of Stereotaxis' products.
- Technological advancements in alternative treatment options may reduce the demand for Stereotaxis' robotic navigation systems.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.